PPARs: Regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α

Future Cardiology

Volumn 13, Issue 3, 2017, Pages 259-278

  Han, Lu ^a,b   Shen, Wen Jun ^a,b   Bittner, Stefanie ^a   Kraemer, Fredric B ^a,b   Azhar, Salman ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; dyslipidemia; fibrates; insulin resistance; lipid and glucose homeostasis; metabolic diseases; NAFLD; obesity

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALEGLITAZAR; CHIGLITAZAR; CHOLINE FENOFIBRATE; CIPROFIBRATE; CLOFIBRATE; ELAFIBRANOR; FENOFIBRATE; FENOFIBRATE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIGLITAZAR; LOBEGLITAZONE; MURAGLITAZAR; NAVEGLITAZAR; PEMAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIRINIXIC ACID; PLACEBO; RAGAGLITAZAR; RETINOID X RECEPTOR; SAROGLITAZAR; SIMVASTATIN; TESAGLITAZAR; TRIACYLGLYCEROL; UNINDEXED DRUG;

ALBUMINURIA; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DYSLIPIDEMIA; FATTY ACID OXIDATION; GENE CONTROL; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; LIPODYSTROPHY; METABOLIC REGULATION; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIDE EFFECT; VASCULAR SMOOTH MUSCLE CELL; AGONISTS; ANIMAL; CLINICAL TRIAL (TOPIC); MOUSE; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; MICE; PPAR ALPHA;

EID: 85020841767     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca-2016-0059     Document Type: Review

References (159)

1. WHO. Cardiovascular disease (2016). www.who.int/cardiovascular-disease/en
2. CDC and Prevention, Division for Heart Disease and Stroke Prevention. Heart disease fact sheet (2016). www.cdc.gov/dhdsp/data-statistics/fact
3. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67(5), 968-977 (1983)
4. Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation 113(6), 898-918 (2006)
5. Mathew B, Francis L, Kayalar A, Cone J. Obesity: effects on cardiovascular disease and its diagnosis. J. Am. Board Fam. Med. 21(6), 562-568 (2008)
6. Kachur S, Lavie CJ, De Schutter A, Milani RV, Ventura HO. Obesity and cardiovascular diseases. Minerva Med. doi:10.23736/S0026-4806.17.05022-4 (2017) (Epub ahead of print)
7. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 241(19), 2035-2038 (1979)
8. Fuller JH, Shipley MJ, Rose G, Jarret RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br. Med. J. (Clin. Res. Ed) 287(6396), 867-870 (1983)
9. Haffner SM, Lehto S, Rönnemaa T, Pyörälä T, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339(4), 229-234 (1998)
10. Lorber D. Importance of cardiovascular disease risk management in patients with Type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes. 7, 169-183 (2014)
11. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311(8), 806-814 (2014)
12. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA 314(10), 1021-1029 (2015)
13. Hurby A, Hu F. The epidemiology of obesity a big picture. Pharmacoeconomics 33(7), 673-689 (2015)
14. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 34(6), 1249-1257 (2011)
15. Guaringuata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2030. Diabetes Res. Clin. Pract. 103(2), 137-149 (2014)
16. Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013 a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384(9945), 766-781 (2014)
17. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365(9468), 1415-1428 (2005)
18. Samson SL, Garbor AJ. Metabolic syndrome. Endocrinol. Metab. Clin. North Am. 43(1), 1-23 (2014)
19. Grundy SM. Metabolic syndrome update. Trends Cardiovasc. Med. 26(4), 364-373 (2016)
20. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome a summary of the evidence. Diabetes Care 28(7), 1769-1778 (2005)
21. Mottillo S, Filion KB, Genest J et al. The metabolic syndrome and cardiovascular risk a systemic review and meta-analysis. J. Am. Coll. Cardiol. 56(14), 1113-1132 (2010)
22. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 31(9), 1898-1904 (2008)
23. O'Neill S, O'Driscoll L. Metabolic syndrome a closer look at the growing epidemic and its associated pathologies. Obes. Rev. 16(10), 1-12 (2015)
24. Kelli HM, Kassas I, Lattouff OM. Cardio metabolic syndrome a global epidemic. J. Diabetes Metab. 6(3), 513 (2015)
25. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346(16), 1221-1231 (2002)
26. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. 5, 145-171 (2010)
27. Rinella ME. Nonalcoholic fatty liver disease a systematic review. JAMA 313(22), 2263-2273 (2015)
28. Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu. Rev. Pathol. 11, 451-496 (2016)
29. Sayiner M, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin. Liver Dis. 20(2), 205-214 (2016)
30. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1), 73-84 (2016)
31. Rinella ME, Sanyal AJ. Management of NAFLD a stage-based approach. Nat. Rev. Gastroenterol. Hepatol. 13(4), 196-205 (2016)
32. Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism 65(8), 1151-1160 (2016)
33. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2(11), 901-910 (2014)
34. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease a precursor of the metabolic syndrome. Dig. Liver Dis. 47(3), 181-190 (2015)
35. Wainwright P, Byrne CD. Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome. Int. J. Mol. Sci. 17(3), 367 (2016)
36. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat. Rev. Endocrinol. 7(8), 456-465 (2011)
37. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10(6), 330-344 (2013)
38. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease a novel cardiometabolic risk factor for Type 2 diabetes and its complications. J. Clin. Endocrinol. Metab. 98(2), 483-495 (2013)
39. Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic fatty liver disease a pathogenic duo. Endocr. Rev. 34(1), 84-129 (2013)
40. Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr. Gastroenterol. Rep. 11(1), 50-55 (2009)
41. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363(14), 1341-1350 (2010)
42. Hyogo H, Chayama K, Yamagishi S. Nonalcoholic fatty liver disease and cardiovascular disease. Curr. Pharm. Des. 20(14), 24031-2411 (2014)
43. Michalik L, Auwerx J, Berger JP et al. International Union of Pharmacology. LXI. peroxisome proliferator-activated receptors. Pharmacol. Rev. 58(4), 726-741 (2006)
44. Bookout AL, Jeong Y, Downes M et al. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126(4), 789-799 (2006)
45. Kliewer SA, Forman BM, Blumberg B et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl Acad. Sci. USA 91(15), 7355-7359 (1994)
46. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α,-β, and-γ in the adult rat. Endocrinology 137(1), 354-366 (1996)
47. Auboeuf D, Rieussel J, Fajas L. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46(8), 1319-1327 (1997)
48. Berger J, Moller DE. The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435 (2002)
49. Chen YE, Fu M, Zhhang J et al. Peroxisome proliferator-activated receptors and the cardiovascular system. Vitam. Horm. 66, 157-188 (2003)
50. Castrillo A, Tontonoz P. PPARs in atherosclerosis: the clot thickens. J. Clin. Invest. 114(11), 1538-1540 (2004)
51. Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome prolifertaor-activated receptors and inflammation. Pharmacol. Ther. 110(3), 371-385 (2006)
52. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul. Pharmacol. 45(1), 19-28 (2006)
53. Finck BN. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc. Res. 73(2), 269-277 (2007)
54. Duan SZ, Usher MG, Mortensen RM. PPARs: the vasculature, inflammation and hypertension. Curr. Opin. Nephrol. Hypertens. 18(2), 128-123 (2009)
55. Wang Y-X. PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res. 20(2), 124-137 (2010)
56. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Cir. Res. 108(8), 1002-1016 (2011)
57. Liss KHH, Finck BN. PPARs and nonalcoholic fatty liver disease. Biochimi. doi:10.1016/j.biochi.2016.11.009 (2016) (Epub ahead of print)
58. Gross B, Pawlak M, Lefebvre P, Staels B. PPARs in obesity-induced T2DM, dyslipidemia and NAFLD. Nat. Rev. Endocrinol. 13(1), 36-39 (2017)
59. Francis GA, Annicotte JS, Auwerx J. PPAR-α effects on the heart and other vascular tissues. Am. J. Physiol. Heart Circ. Physiol. 285(1), H1-H9 (2003)
60. Barish GD, Narkar VA, Evans RM. PPAR-δ a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116(3), 590-597 (2006)
61. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR-α in energy metabolism and vascular homeostasis. J. Clin. Invest. 116(3), 571-580 (2003)
62. Semple RK, Chatterjee VK, O'Rahilly S. PPARγ and human metabolic disease. J. Clin. Invest. 116(3), 581-589 (2006)
63. Ehrenborg E, Krook A. Regulation of skeletal muscle physiology and metabolism by peroxisome prolifertaor-activated receptor and delta;. Pharmacol. Rev. 61(3), 373-393 (2008)
64. Takano H, Komuro I. Peroxisome proliferator-activated receptor γ and cardiovascular diseases. Circ. J. 73(2), 214-220 (2009)
65. Pyper SR, Viswakarma N, Yu S, Reddy JK. PPAR-α: energy combustion, hypolipidemia, inflammation and cancer. Nucl. Recept. Signal. 8, e002 (2010)
66. Ahmadian M, Suh JM, Hah N, Liddle C et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat. Med. 19(5), 557-566 (2013)
67. Bojic LA, Huff MW. Peroxisome proliferator-activated receptor δ a multifaceted metabolic player. Curr. Opin. Lipidol. 24(12), 171-177 (2013)
68. Ding Y, Yang KD, Yang Q. The role of PPARδ signaling in the cardiovascular system. Prog. Mol. Biol. Trans. Sci. 121, 451-473 (2014)
69. Kersten S. Integrated physiology and systems biology of PPAR-and alpha. Mol. Metab. 3(4), 354-371 (2014)
70. Tan NS, Vázquez-Carrera M, Montagner A, Sng MK, Guillou H, Wahli W. Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/ and delta;. Prog. Lipid Res. 64, 98-122 (2016)
71. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr. Atheroscler. Rep. 6(20), 148-157 (2004)
72. Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, Schwartzbard A. Fibrate therapy: an update. Cardiol. Rev. 16(3), 129-141 (2008)
73. Alagona P. Fenofibric acid a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vasc. Health Risk Manag. 6, 351-362 (2010)
74. Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol. 11, 140 (2012)
75. Yki-Järvinen H. Thiazolidinediones. N. Engl. J. Med. 351(11), 1106-1118 (2004)
76. Barnett AH. Redefining the role of thiazolidinediones in the management of Type 2 diabetes. Vasc. Health Risk Manag. 5(1), 141-151 (2009)
77. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol. Metab. 23(5), 205-215 (2012)
78. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in Type 2 diabetes. Cell Metab. 20(4), 573-591 (2014)
79. Azhar S. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 6(5), 657-691 (2010)
80. Sher T, Yi HF, McBride OW, Gonzalez FJ. CDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32(21), 5598-5604 (1993)
81. Viswakarma N, Jia Y, Bai L et al. Coactivators in PPAR-regulated gene expression. PPAR Res. 2010, 250126 (2010)
82. Mottis A, Mouchiround L, Auwerx J. Emerging roles of the corepressors NCoR1 and SMART in homeostasis. Genes Dev. 27(8), 819-835 (2013)
83. Chakravarthy MV, Lodhi IJ, Yin L et al. Identification of a physiologically relevant endogenous ligand for PPAR-α in liver. Cell 138(3), 476-488 (2009)
84. Abbott BD. Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR-α), beta (PPARβ), and gamma (PPARγ) in rodent and human development. Reprod. Toxicol. 27(3-4), 246-257 (2009)
85. Gouni-Berhold I, Krone W. Peroxisome proliferator-activated receptor α (PPAR-α) and atherosclerosis. Curr. Drug targets Cardiovasc. Hematol. Disord. 5(6), 513-523 (2005)
86. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrtaes on lipid and lipoprotein metabolism. Circulation 98(19), 2088-2093 (1998)
87. Krauss RM. Lipids and lipoproteins in patients with Type 2 diabetes. Diabetes Care 27(6), 1496-1504 (2004)
88. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc. Diabetol. 11, 125 (2012)
89. Katsiki N, Nikolic D, Montalto G, Banach M, Mikhilidis DP, Rizzo M. The role of fibrate treatment in dyslipidemia: an overview. Curr. Pharm. Des. 19(17), 3124-3131 (2013)
90. Rosenson RS. Lipid lowering with fibric acid derivatives (2016). www.uptodate.com/contents/lipid-lowering
91. Patsouris D, Müller M, Kersten S. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance. Curr. Opin. Investig. Drugs 5(10), 1045-1050 (2004)
92. Zandbergen F, Plutzky J. PPAR-α in atherosclerosis and inflammation. Biochim. Biophys. Acta 1771(8), 972-982 (2007)
93. Shipman KE, Strange RC, Ramachandran S. Use of fibrates in the metabolic syndrome a review. World J. Diabetes. 7(5), 74-88 (2016)
94. Duval C, Müller M, Kersten S. PPAR-α and dyslipidemia. Biochim. Biophys. Acta 1771(8), 961-971 (2007)
95. Huang XS, Zhao SP, Bai L, Hu M, Zhao W, Zhang Q. Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-and alpha;. Br. J. Pharmacol. 158(3), 706-712 (2009)
96. Rakhshandehroo M, Knoch B, Müller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010, 612089 (2010)
97. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37(5), 907-925 (1996)
98. Oosterveer MH, Grefhorst A, van Dijk TH et al. Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. J. Biol. Chem. 284(49), 34036-34044 (2009)
99. Contreras AV, Torres N, Tovar AR. PPAR-α as a key nutritional and environmental sensor for metabolic adaptation. Adv. Nutr. 4(4), 439-452 (2013)
100. Muoio DM, Way JM, Tanner CJ et al. Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 51(4), 901-909 (2002)
101. Djouadi F, Aubey F, Schlemmer D, Bastin J. Peroxisome proliferator activated receptor δ (PPARδ) agonist but not PPAR-α corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J. Clin. Endocrinol. Metab. 90(3), 1791-1797 (2005)
102. Abbot EL, McCormack JG, Reynet C, Hassall DG, Buchan KW, Yeaman SJ. Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells. FEBS J. 272(12), 3004-3014 (2005)
103. Sugden MC, Holness MJ. Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases. Arch. Physiol. Biochem. 112(3), 139-149 (2006)
104. Patel MS, Srinivasan M, Strutt B, Mahmood S, Hill DJ. The pyruvate dehydrogenase complexes: structure-based function and regulation. J. Biol. Chem. 289(24), 16615-16623 (2014)
105. Wu P, Inskeep K, Bowker-Kinley MM, Popov KM, Harris RA. Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. Diabetes 48(8), 1593-1599 (1999)
106. Zhang J, Phillips DI, Wang C, Byrne CD. Human skeletal muscle PPAR expression correlates with fat metabolism gene expression but not BMI or insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 286(2), E168-E175 (2004)
107. Souza AT, Cornwell PD, Dai X, Caguyong MJ, Ulrich RG. Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle. Toxicol. Sci. 92(2), 578-586 (2006)
108. Minnich A, Tian N, Byan L, Bilder G. A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 280(2), E270-E279 (2001)
109. Bishop-Baily D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol. 129(5), 823-834 (2000)
110. Plutzky J. Peroxisome prolifertaor-activated receptors in vascular biology and atherosclerosis: emerging insights from evolving paradigms. Curr. Atheroscler. Rep. 2(4), 416-421 (2000)
111. Vosper H, Khoudoli GA, Graham TL, Palmer CNA. Peroxisome proliferator-activated receptor agonists, hyperlipidemia, and atherosclerosis. Pharmacol. Ther. 95(1), 47-62 (2002)
112. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94(9), 1168-1178 (2004)
113. Israelian-konaraki Z, Reaven PD. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiol. Rev. 103(1), 1-9 (2005)
114. Tordjman K, Bernal-Mizrachi C, Zemany L et al. PPAR-α deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 107(8), 1025-1034 (2001)
115. Duez H, Chao YS, Hernandez M et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem. 277(50), 48051-48057 (2002)
116. Li AC, Binder CJ, Gutierrez A et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR-α, β/δ, and and gamma;. J. Clin. Invest. 114(11), 1564-1576 (2004)
117. Hennuyer N, Tailleux A, Torpier G et al. PPAR-α, but not PPARγ activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 25(9), 1897-1902 (2005)
118. Babaev VR, Ishiguro H, Ding L et al. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 116(12), 1404-1412 (2007)
119. Chira EC, McMillen TS, Wang S et al. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis 195(1), 100-109 (2007)
120. Zhang BC, Li WM, Li XK, Zhu MY, Che WL, Xu YW. Tesaglitazar ameliorates non-alcoholic fatty liver disease and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient mice. Exp. Ther. Med. 4(6), 987-992 (2012)
121. Van der Hoorn JW, Jukema WJ, Havekes LK et al. The dual PPAR-α/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE 3Leiden CETP transgenic mice. Br. J. Pharmacol. 156(7), 1065-1075 (2009)
122. Zadelaar AS, Boesten LS, Jukema JW et al. Dual PPAR-α/γ agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE 3Leiden mice. Arterioscler. Thromb. Vasc. Biol. 26(11), 2560-2566 (2006)
123. Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC. Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis 195(1), 17-22 (2007)
124. Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta 1771(8), 952-960 (2007)
125. Berrabah W, Aumercier P, Lefebvre P, Staels B. Control of nuclear receptor activities in metabolism by post-translational modifications. FEBS Lett. 585(11), 1649-1650 (2011)
126. Lazennec G, Canaple L, Saugy D, Wahli W. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol. Endocrinol. 14(12), 1962-1975 (2000)
127. Shalev A, Seigrist-kaiser CA, Yen PM et al. The peroxisome prolifertaor-activated receptor α is a phosphoprotein: regulation by insulin. Endocrinology 137(10), 4499-4502 (1996)
128. Juge-Aubry CE, Hammer E, Siegrist-Kaiser C et al. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor α by phosphorylation of a ligand-independent trans-activating domain. J. Biol. Chem. 274(15), 10505-10510 (1999)
129. Passily P, Schohn H, Jannin B et al. Phosphorylation of peroxisome proliferator-activated receptor α in rat Fao cells and stimulation by ciprofibrate. Biochem. Pharmacol. 58(6), 1001-1008 (1999)
130. Barger PM, Browning AC, Garner AN, Kelly DP. p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor α a potential role in the cardiac metabolic stress response. J. Biol. Chem. 276(48), 44495-44501 (2001)
131. Diradourian C, Le May C, Caüzac M, Girard J, Burnol A, Pégorier J. Involvement of ZIP/p62 in the regulation of PPAR-α transcriptional activity by p38 MAPK. Biochim. Biophys. Acta 1781(5), 239-244 (2008)
132. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated PPAR-α during cardiac hypertrophy. J. Clin. Invest. 105(12), 1723-1730 (2000)
133. Blanquart C, Mansouri R, Paumelle R, Fruchart J, Staels B, Glineur C. The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor and alpha;. Mol. Endocrinol. 18(8), 1906-1918 (2004)
134. Vanden Heuvel JP. Peroxisome proliferator-activated receptors a critical link among fatty acids, gene expression and carcinogenesis. J. Nutr. 129(Suppl. 2), S575-S580 (1999)
135. Gray JP, Burns KA, Leas TL, Perdew GH, Vanden Heuvel JP. Regulation of peroxisome-prolifertaor activated receptor α by protein kinase C. Biochemistry 44(30), 10313-103210 (2005)
136. Jacob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst. Rev. 11, CD009753 (2016)
137. Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst. Rev. 10, CD009580 (2015)
138. Choi HD, Shin WG. Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia a meta-analysis. Curr. Med. Res. Opin. 30(1), 1-10 (2014)
139. Milionis H. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe? Expert Opin. Drug Saf. 13(3), 267-269 (2014)
140. Filippatos TD, Elisaf MS. Safety considerations with fenofibrates/simvastatin combination. Expert Opin. Drug Saf. 14(9), 1481-1493 (2015)
141. Wright MB, Bortolini M, Tadayyon M, Bopst M. Minireview: challenges and opportunities in development of PPAR agonists. Mol. Endocrinol. 28(11), 1756-1768 (2014)
142. Jani RH, Pai V, Jariwala G et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in Type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastin therapy (PRESS VI). Diabetes Technol. Ther. 16(2), 63-71 (2014)
143. Pai V, Paneerselvam A, Mukhopadhyay S et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg copared to pioglitazone 46 mg in diabetic dyslipidemia (PRESS V). J. Diabetes Sci. Technol. 8(1), 132-141 (2014)
144. Joshi SR. Saroglitazar for the treatment of dyslipidemia in diabetic patients. Expert. Opin. Pharmacother. 16(4), 597-606 (2015)
145. Sosale A, Saboo B, Sosale B. Saroglitazar for the treatment of hypertriglyceridemia in patients with Type 2 diabetes: current evidence. Diabetes Metab. Syndr. Obes. 8, 189-196 (2015)
146. Deshpande A, Toshniwal H, Joshi S, Rani RH. A prospective, multicenter, open-label single-arm exploratory study to evaluate efficacy and safety of Saroglitazar on hypertriglyceridemia in HIV associatted lipodystrophy. PLoS ONE 11(1), e0146222 (2016)
147. Kim SG, Kim DM, Woo JT et al. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks a multicenter, randomized, double-blind, parallel-group, placebo control. PLoS ONE 9(4), e92843 (2014)
148. Kim SH, Kim SG, Kim DM et al. Safety and efficacy of lobeglitazone monotherapy in patients with Type 2 diabetes mellitus over 52 weeks: an open-label expansion study. Diabetes Res. Clin. Pract. 10(3), E27-E30 (2015)
149. Lee YH, Kim JH, Kim SR et al. Lobeglitazone, a novel thiazolidinedione, improves nonalcoholic fatty liver disease in Type 2 diabetes: its efficacy and predictive factors related to responsiveness. J. Korean Med. Sci. 32(1), 60-69 (2017)
150. Lim S, Lee KS, Lee JE et al. Effect of a new PPAY-γ agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the the development of atherosclerosis. Atherosclerosis 243(1), 107-119 (2015)
151. Li PP, Shan S, Chen YT et al. The PPAR-α/γ dual agonists chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Br. J. Pharmacol. 148(5), 610-618 (2006)
152. He BK, Nig ZQ, Li ZB et al. In vitro and in vivo charcterization of chiglitazar, a newly identified PPAR pan agonist. PPAR Res. 2012, 546-548 (2012)
153. Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR-α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolis. Diabetes Care 34(9), 2008-2014 (2011)
154. Cariou B, Hanf R, Lambert-Porcheron S et al. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 36(10), 2923-2930 (2013)
155. Staels B, Rubenstrunk A, Noel B et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor α/δ agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58(6), 1941-1952 (2013)
156. Hanf R, Millatt LJ, Cariou B et al. The dual peroxisome prolifertaor-activated receptor α/δ agonist GFT505 exerts anti-diabetic effects in de/db mice without peroxisome proliferator-activated receptor γ-associated adverse cardiac effects. Diab. Vasc. Dis. Res. 11(6), 440-447 (2014)
157. Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin. Pharmacother. 15(4), 493-503 (2014)
158. Gryn SE, Hegele RA. New oral agents for treating dyslipidemia. Curr. Opin. Lipidol. 27(6), 579-584 (2016)
159. Takei K, Han SI, Murayama Y et al. The selective PPAR-α modultor K-877 efficiently activates the PPAR-α pathway and improves lipid metabolism in mice. J. Diabetes Investig. doi:10.1111/jdi.12621 (2017) (Epub ahead of print)